Vertex Pharmaceuticals Gross Profit

Vertex Pharmaceuticals (VRTX) currently reports a gross profit of $11B as of June 2026. That compares with $9.8B in the prior-year period — up 10.1% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Vertex Pharmaceuticals's gross profit history and peer comparisons.

Vertex Pharmaceuticals's gross profit increased from $9.8B to $11B — a 10.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vertex Pharmaceuticals's gross profit of $11B is lower than the Healthcare sector average of $67B. That is roughly 83.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Vertex Pharmaceuticals reported $11B in gross profit as of June 2026. That compares with $9.8B in the prior-year period — up 10.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $11B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals, and consider following VRTX for alerts when major investors trade the stock.